GLP-1 therapy may calm psoriasis and hidradenitis suppurativa beyond weight loss, and holistic metabolic care can address aesthetic concerns, according to Walker.
Daniel Walker, MD, FAAD, board-certified dermatologist at US Dermatology Partners Keller and Grapevine in Texas, explored which dermatology patient populations may derive the greatest benefit from glucagon-like peptide 1 (GLP-1) receptor agonists.
He noted that emerging evidence suggests that patients with inflammatory skin diseases such as psoriasis and hidradenitis suppurativa who also have comorbid obesity or metabolic syndrome appear to experience the most meaningful clinical improvements. This observation is consistent with the primary indications of GLP-1 receptor agonists in weight management and metabolic disease. However, Walker highlighted that improvements in skin disease are not solely dependent on weight loss.
“The weight loss and the skin improvement are often linked, but it’s not completely dependent on each other,” he said.
Several studies indicate that patients may experience reductions in disease severity even in the absence of significant weight reduction, suggesting a direct anti-inflammatory effect. Despite these promising findings, GLP-1 receptor agonists remain investigational in dermatology. Their role is best considered adjunctive, particularly in patients with overlapping metabolic comorbidities, where addressing systemic inflammation may enhance overall disease control.
Walker also addressed growing concerns around aesthetic changes associated with GLP-1–induced weight loss, sometimes referred to as “Ozempic face.” He emphasized that these effects are typical of any rapid or significant weight reduction. As such, management should focus on preventive and holistic strategies rather than attributing the issue solely to the medication.
He advocates for a comprehensive approach that includes gradual, medically supervised weight loss, attention to nutritional status (particularly adequate protein intake), and incorporation of strength training to preserve lean body mass. For patients experiencing cosmetic concerns, interventions such as dermal fillers may provide effective symptomatic improvement.
Ultimately, Walker underscored the importance of a multifaceted care model that integrates dermatologic treatment with metabolic health optimization. This approach not only improves skin outcomes but also supports overall patient well-being, aligning with the evolving understanding of inflammatory skin diseases as systemic conditions requiring interdisciplinary management.
